Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $88.00 | Neutral | UBS |
| 5/14/2024 | $140.00 | Overweight | Stephens |
| 5/6/2024 | $50.00 → $97.00 | Underperform → Market Perform | Leerink Partners |
| 10/27/2023 | $85.00 | Perform → Outperform | Oppenheimer |
| 8/21/2023 | $65.00 → $66.00 | Buy | Needham |
| 7/31/2023 | $55.00 → $82.00 | Equal Weight → Overweight | Wells Fargo |
| 6/5/2023 | $48.00 → $43.00 | Market Perform → Underperform | SVB Securities |
| 1/3/2023 | $41.00 | Underweight → Equal Weight | Wells Fargo |
SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)
SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)
SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)
-- Company to present registrational PIONEER trial results at 2023 AAAAI Annual Meeting -- CAMBRIDGE, Mass., Nov. 22, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) for AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM). AYVAKIT was designed to potently and selectively inhibit D816V mutant KIT, the underlying cause of SM in about 95 percent of cases. The submission includes data from the registrationa
Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line osimertinib treatment Study demonstrates need to identify C797X-driven resistance and tailor therapy options appropriately for patients with EGFR-mutant NSCLC Guardant Health Inc. (NASDAQ:GH), a leading precision oncology company, and Blueprint Medicines Corporation (NASDAQ:BPMC) announced today they are presenting new data demonstrating that the EGFR C797X mutation is the most common resistance mechanism to osimertinib therapy for patients with advanced non-small cell lung cancer (NSCLC). The results ar
-- Report highlights efforts to deliver sustainable value to patients and communities, foster a diverse and empowered workforce, and operate with exceptional integrity -- CAMBRIDGE, Mass., July 14, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today published its first Corporate Responsibility Report, highlighting its long-standing commitment to deliver sustainable value to patients with cancer and blood disorders, as well as the communities in which it operates. The report, which formalizes the company's efforts to track and report environmental, social and governance (ESG) standards and initiatives, includes summaries and performance metrics that demonstrate its purpos
10-Q - Blueprint Medicines Corp (0001597264) (Filer)
8-K - Blueprint Medicines Corp (0001597264) (Filer)
10-Q - Blueprint Medicines Corp (0001597264) (Filer)
4 - Blueprint Medicines Corp (0001597264) (Issuer)
4 - Blueprint Medicines Corp (0001597264) (Issuer)
4 - Blueprint Medicines Corp (0001597264) (Issuer)
-- Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 -- -- On track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end -- CAMBRIDGE, Mass., Oct. 30, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results, provided a business update for the third quarter ended Sept 30, 2024, and provided updated financial guidance. "With another strong quarter of AYVAKIT revenue perform
CAMBRIDGE, Mass., Oct. 16, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, October 30, 2024, to report its third quarter 2024 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 387547. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at h
-- Achieved $114.1 million in AYVAKIT net product revenues in the second quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $435 million to $450 million for 2024 -- -- Initiated Phase 1 healthy volunteer trial of wild-type KIT inhibitor BLU-808 -- CAMBRIDGE, Mass., Aug. 1, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results, provided a business update for the second quarter ended June 30, 2024, and provided updated financial guidance. "This quarter marks a milestone, as we celebrate one full year since the U.S. a
UBS initiated coverage of Blueprint Medicines with a rating of Neutral and set a new price target of $88.00
Stephens initiated coverage of Blueprint Medicines with a rating of Overweight and set a new price target of $140.00
Leerink Partners upgraded Blueprint Medicines from Underperform to Market Perform and set a new price target of $97.00 from $50.00 previously
Morgan Stanley analyst Michael Ulz maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and raises the price target from $110 to $115.
Oppenheimer analyst Matthew Biegler maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and raises the price target from $114 to $125.
During the last three months, 17 analysts shared their evaluations of Blueprint Medicines (NASDAQ:BPMC), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 8 5 3 0 1 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 4 2 3 0 1 3M Ago 3 2 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting an average target of $116.35, a high estimate of $168.00, and a low estimate of $75.00. Witnessing a positiv
-- Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 -- -- On track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end -- CAMBRIDGE, Mass., Oct. 30, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results, provided a business update for the third quarter ended Sept 30, 2024, and provided updated financial guidance. "With another strong quarter of AYVAKIT revenue perform
CAMBRIDGE, Mass., Oct. 16, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, October 30, 2024, to report its third quarter 2024 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 387547. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at h
CAMBRIDGE, Mass., Sept. 10, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced its participation in the following upcoming virtual investor conferences: Stifel 2024 Immunology and Inflammation Virtual Summit on Tuesday, September 17, 2024, at 2:00 p.m. ET.TD Cowen's Chronic Urticaria Summit on Friday, September 20, 2024, at 11:00 a.m. ET.A live webcast of each presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcasts will be archived on B